The growing use of genomic data in healthcare aims to balance predictive and diagnostic needs by supporting both disease prevention and clinical decision-making. Yet, the predictive potential of ...

Patricia is a Policy Analyst in the humanities team. She works on legal and ethical issues for data protection and data governance introduced by scientific health innovations. She is completing a PhD ...

Synthetic data – artificial data that closely mimic the properties and relationships of real data – are not a new concept but technological advances have led to great optimism about their potential ...

Pharmacogenomics, a branch of precision medicine, is the study of genomic characteristics that affect how individuals respond to drugs. It could be useful for improving treatment for a wide variety of ...

Colin is the PHG Foundation’s Head of Humanities. He leads the team’s work on legal and ethical issues across genomics, novel health technologies, innovative biomedical research and data. Some key ...

Functional genomics is a field of molecular biology where researchers attempt to understand the complex relationship between genotype and phenotype. While genetics and genomics cover the study of ...

Expanded newborn screening: A review of the evidence is a systematic review of the evidence to support expansion of current UK newborn screening provision to include any of five additional forms of ...

This report explores privacy and anonymity in the context of genetic and genomic data: the protection of privacy and anonymity is regarded by some as of absolute importance, but increasingly, this ...

From wearables for health monitoring and self-care apps, to machine learning analysis of medical images, the potential of digital technologies to revolutionise healthcare has commanded many headlines.

Science and technologies have the potential to transform the healthcare landscape over the next 20 years. Such a transformation will be directly influenced by a range of factors including the complex, ...

A workshop was held in London on 9 March 2004 to evaluate the current status of the cancer genomics field, to identify those areas closest to clinical implementation and to consider progress and ...